UNSPSC 51313416: Betahistine hydrochloride

This classification denotes a vasodilating agent with the molecular formula C8H12N2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 49K58SMZ7U, chemically known as 2-pyridineethanamine, n-methyl-, dihydrochloride but more generally known as betahistine dihydrochloride, which bears US NIH Compound Identifier 68643. The base compound, Betahistine, most often comes in base, dihydrochloride, hydrochloride, and mesylate forms.

UNSPSC 51313416 Betahistine hydrochloride is a Commodity code that nominally names a specific pharmaceutical active ingredient, but state and local procurement activity tagged under this code does not reflect actual betahistine purchases. Instead, the recent opportunities show a much broader scope: state and local governments are using this code tag to solicit generic pharmaceuticals, over-the-counter products, naloxone, drug deactivation systems, and direct-to-manufacturer prescription programs that serve public health, community health, and state employee benefit functions. The issuing bodies span county health departments, state health and human services agencies, and multi-state cooperative purchasing consortia. The mismatch between the code's nominal pharmaceutical ingredient and the actual procurement scope suggests either tagging inconsistency in the source systems or a broader interpretation of the code in practice than its name suggests.

Recent activity includes Seminole County, Florida's July 2026 IFB for naloxone and safe drug deactivation systems (1,900 units annually), the Texas Health and Human Services Commission's April 2026 RFI on direct-to-manufacturer prescription programs, and the Minnesota Multistate Cooperative Purchasing Alliance's March 2026 RFP for generic multi-source pharmaceuticals and OTC products serving state and local facilities across participating jurisdictions including Oregon. The geographic spread covers Florida, Texas, Minnesota, and Oregon, with multi-state cooperative purchasing playing a significant role in larger-scale pharmaceutical procurement. Given the code's nominal specificity to a single drug ingredient and the actual procurement scope spanning multiple product categories and delivery models, firms should verify code assignments in specific opportunities before pursuing, as the tagging does not consistently reflect work actually being bought.